Skip Navigation LinksHome > November 2010 - Volume 126 - Issue 5 > Treatment of Male Pattern Baldness with Botulinum Toxin: A P...
Plastic & Reconstructive Surgery:
doi: 10.1097/PRS.0b013e3181ef816d
Viewpoints

Treatment of Male Pattern Baldness with Botulinum Toxin: A Pilot Study

Freund, Brian J. D.D.S., M.D.; Schwartz, Marvin D.D.S., M.Sc.

Free Access
Article Outline
Collapse Box

Author Information

Crown Institute; Pickering, Ontario, Canada

Correspondence to Dr. Freund, 49 Main Street South, Uxbridge, Ontario L9P 1J4, Canada, freund@crowninstitute.com

This clinical trial has been registered as “Treatment of Male Pattern Baldness with Botulinum Toxin” at http://www.clinicaltrials.gov/ClinicalTrials.gov with identifier NCT00965640.

Back to Top | Article Outline

Sir:

Figure. No caption a...
Image Tools

We would like to present the results of an open-label pilot study using botulinum toxin type A (Botox; Allergan, Inc., Irvine, Calif.) for the treatment of androgenetic alopecia. This form of alopecia is believed to be caused by a genetically predisposed sensitivity of hair follicles to the toxic effects of dihydrotestosterone, a metabolite of testosterone. Medical treatment of androgenetic alopecia has previously only been moderately effective using systemic drugs such as finasteride, a 5α-reductase inhibitor.1

In this ethically approved study, 50 male subjects aged between 19 and 57 years with Norwood/Hamilton ratings of II to IV participated.2 The study was 60 weeks in duration, with 12 weeks of run-in followed by two treatment cycles of 24 weeks each. Subjects were injected with 150 units of Botox (5 units per 0.1 ml saline) into the muscles surrounding the scalp, including frontalis, temporalis, periauricular, and occipitalis muscles in equally divided doses over 30 injection sites. The primary outcome measure was a change in hair count in a fixed 2-cm area using a method described by Canfield.3 Secondary outcome measures included hair loss, measured by having subjects collect loose hair from their pillow with a sticky lint roller, and subjective efficacy using a validated questionnaire. Statistical analysis entailed paired t tests of group means.

Forty subjects completed the study, and no adverse effects were reported. The treatment response rate was 75 percent. Mean hair counts for the entire group showed a statistically significant (p < 0.0001) increase of 18 percent between baseline and week 48 (Table 1), similar to the results reported with Propecia (Merck, Whitehouse Station, N.J.).1 Hair regrowth was objectively visible in some subjects (Fig. 1). Secondary outcome measures were also significantly improved. The reduction in hair loss and increase in hair count did not show a statistically significant correlation. This suggested that longer retention of terminal hairs did not account for the increase in hair count.

Table 1
Table 1
Image Tools
Fig. 1
Fig. 1
Image Tools

Mechanistically, the scalp behaves like a drum skin with tensioning muscles around the periphery. These muscle groups—the frontalis, occipitalis, and periauricular muscles and to a minor degree the temporalis—can create a “tight” scalp when chronically active. Because the blood supply to the scalp enters through the periphery, a reduction in blood flow would be most apparent at the distal ends of the vessels, specifically, the vertex and frontal peaks. Areas of the scalp with sparse hair growth have been shown to be relatively hypoxic, have slow capillary refill, and to have high levels of dihydrotestosterone.4

Conceptually, Botox “loosens” the scalp, reducing pressure on the perforating vasculature, thereby increasing blood flow and oxygen concentration. The enzymatic conversion of testosterone to dihydrotestosterone is oxygen dependent. In low-oxygen environments, the conversion of testosterone to dihydrotestosterone is favored; whereas in high-oxygen environments, more testosterone is converted to estradiol.4 Blood flow may therefore be a primary determinant in follicular health. Strategically placed Botox injections appear able to indirectly modify this variable, resulting in reduced hair loss and new hair growth in some men with androgenetic alopecia.

Back to Top | Article Outline

DISCLOSURE

The investigators have received support in the form of unrestricted educational grants from Allergan Inc. (Irvine, Calif.) within the past 5 years. The authors hold intellectual property rights related to the process described in this study in both the United States and the European Union. This study was not supported by any commercial entity or government agency.

Brian J. Freund, D.D.S., M.D.

Marvin Schwartz, D.D.S., M.Sc.

Crown Institute

Pickering, Ontario, Canada

Back to Top | Article Outline

REFERENCES

1. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39:578–589.

2. Norwood OT. Male pattern baldness: Classification and incidence. South Med J. 1975;68:1359–1365.

3. Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin. 1996;14:713–721.

4. Goldman BE. Transcutaneous PO2 of the scalp in male pattern baldness. Plast Reconstr Surg. 1996;97:1109–1116.

Back to Top | Article Outline
Section Description

Viewpoints, pertaining to issues of general interest, are welcome, even if they are not related to items previously published. Viewpoints may present unique techniques, brief technology updates, technical notes, and so on. Viewpoints will be published on a space-available basis because they are typically less timesensitive than Letters and other types of articles. Please note the following criteria:

* Text—maximum of 500 words (not including references)

* References—maximum of five

* Authors—no more than five

* Figures/Tables—no more than two figures and/or one table

Authors will be listed in the order in which they appear in the submission. Viewpoints should be submitted electronically via PRS' enkwell, at www.editorialmanager.com/prs/. We strongly encourage authors to submit figures in color.

We reserve the right to edit Viewpoints to meet requirements of space and format. Any financial interests relevant to the content must be disclosed. Submission of a Viewpoint constitutes permission for the American Society of Plastic Surgeons and its licensees and assignees to publish it in the Journal and in any other form or medium.

The views, opinions, and conclusions expressed in the Viewpoints represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.

Cited By:

This article has been cited 2 time(s).

Indian Journal of Dermatology Venereology & Leprology
Androgenetic alopecia: An update
Kaliyadan, F; Nambiar, A; Vijayaraghavan, S
Indian Journal of Dermatology Venereology & Leprology, 79(5): 613-625.
10.4103/0378-6323.116730
CrossRef
Dermatologic Clinics
Hair: What is New in Diagnosis and Management? Female Pattern Hair Loss Update: Diagnosis and Treatment
Mesinkovska, NA; Bergfeld, WF
Dermatologic Clinics, 31(1): 119-+.
10.1016/j.det.2012.08.005
CrossRef
Back to Top | Article Outline

©2010American Society of Plastic Surgeons

Login

Article Tools

Images

Share